{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:15Z","timestamp":1786982295940,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic myeloid leukemia (CML) and\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    -negative\u00a0MPN were thought to be mutually exclusive, but synchronous and sequential cases have been reported. We screened 35,001 patients for\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    fusion or\n                    <jats:italic>JAK2<\/jats:italic>\n                    ,\n                    <jats:italic>CALR<\/jats:italic>\n                    , or\n                    <jats:italic>MPL<\/jats:italic>\n                    mutations to investigate the sequential development of CML and\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    \u00a0negative-MPNs. We discovered that 5.6% had primary CML followed by\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    -negative\u00a0MPN, and 5.8% had the reverse sequence. Notably, we identified higher\n                    <jats:italic>JAK2<\/jats:italic>\n                    variant allele frequencies (VAFs) in patients developing secondary CML. Previous MPN did not compromise the effectiveness of tyrosine kinase inhibitors (TKI) in treating secondary CML. The emergence of secondary MPN appeared to be unrelated to\n                    <jats:italic>JAK2<\/jats:italic>\n                    VAF progression or\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    transcript levels. Our research indicates that newly detected leukocytosis or thrombocytosis should prompt consideration of secondary MPN. It also showed that secondary CML had no negative impact on response to therapy when patients were treated according to CML guidelines.\n                  <\/jats:p>","DOI":"10.1007\/s12185-025-04046-5","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:48:48Z","timestamp":1756968528000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential occurrence of BCR::ABL1-negative\u00a0MPN and CML and vice versa: results from a real world cohort"],"prefix":"10.1007","volume":"122","author":[{"given":"Katrin","family":"Schweneker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pohlkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"25","key":"4046_CR1","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"17","key":"4046_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"7","key":"4046_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7): e270.","journal-title":"PLoS Med"},{"issue":"5","key":"4046_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459\u201368.","journal-title":"N Engl J Med"},{"issue":"10","key":"4046_CR5","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106(10):3370\u20133.","journal-title":"Blood"},{"key":"4046_CR6","unstructured":"WHO. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series 2022; 5th ed.; vol. 11:[Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"issue":"1\u20132","key":"4046_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14740\/jh591","volume":"9","author":"M Lorenzo","year":"2020","unstructured":"Lorenzo M, Grille S, Stevenazzi M. Emergence of BCR-ABL1 chronic myeloid leukemia in a JAK2-V617F polycythemia vera. J Hematol. 2020;9(1\u20132):23\u20139.","journal-title":"J Hematol"},{"issue":"1","key":"4046_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/bjh.13932","volume":"176","author":"P Martin-Cabrera","year":"2017","unstructured":"Martin-Cabrera P, et al. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol. 2017;176(1):135\u20139.","journal-title":"Br J Haematol"},{"issue":"15","key":"4046_CR9","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","volume":"120","author":"M Meggendorfer","year":"2012","unstructured":"Meggendorfer M, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080\u20138.","journal-title":"Blood"},{"issue":"26","key":"4046_CR10","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333.","journal-title":"Blood"},{"issue":"19","key":"4046_CR11","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534\u201344.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4046_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/16078454.2022.2107888","volume":"27","author":"Y Pan","year":"2022","unstructured":"Pan Y, et al. The different variant allele frequencies of type I\/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis. Hematology. 2022;27(1):902\u20138.","journal-title":"Hematology"},{"issue":"5","key":"4046_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","volume":"143","author":"SY Kim","year":"2015","unstructured":"Kim SY, et al. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015;143(5):635\u201344.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"4046_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"7","key":"4046_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"1","key":"4046_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1080\/16078454.2022.2108902","volume":"27","author":"F Tarantini","year":"2022","unstructured":"Tarantini F, et al. JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? Hematology. 2022;27(1):842\u20136.","journal-title":"Hematology"},{"issue":"3","key":"4046_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12185-022-03463-0","volume":"117","author":"MJ Hochman","year":"2023","unstructured":"Hochman MJ, et al. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency. Int J Hematol. 2023;117(3):456\u201362.","journal-title":"Int J Hematol"},{"issue":"6","key":"4046_CR18","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336\u201343.","journal-title":"Leukemia"},{"issue":"12","key":"4046_CR19","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","volume":"118","author":"L Pieri","year":"2011","unstructured":"Pieri L, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood. 2011;118(12):3445\u20136.","journal-title":"Blood"},{"issue":"5","key":"4046_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.21296","volume":"84","author":"S Gattenlohner","year":"2009","unstructured":"Gattenlohner S, et al. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome\/myeloproliferative neoplasm (RARS-T). Am J Hematol. 2009;84(5):306\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"4046_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/10245332.2018.1498182","volume":"23","author":"L De Roeck","year":"2018","unstructured":"De Roeck L, et al. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology. 2018;23(10):785\u201392.","journal-title":"Hematology"},{"issue":"4","key":"4046_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5045\/br.2021.2021089","volume":"56","author":"AJ Lee","year":"2021","unstructured":"Lee AJ, et al. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res. 2021;56(4):259\u201365.","journal-title":"Blood Res"},{"issue":"2","key":"4046_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol. 2019;184(2):176\u201391.","journal-title":"Br J Haematol"},{"issue":"9","key":"4046_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574\u20139.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04046-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:23:40Z","timestamp":1763713420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04046-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04046-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WK, CH and TH declare part ownership of Munich Leukemia Laboratory (MLL). KS, ML, MM, and CP are employed by the MLL Munich Leukemia Laboratory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients had given written informed consent for the use of genetic and clinical data in accordance with the Declaration of Helsinki. The study was approved by our internal institutional review board. This study contains only laboratory data from a large cohort of patients. No clinical trial was performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}